Preserving Genetic Traits: Characterizing Ovarian Borderline Tumor Organoids and Evaluating the Antitumor Activity of Bractoppin, a BRCA1 Carboxy-Terminal Domain (BRCT) Inhibitor
Received Date: Jun 01, 2023 / Published Date: Jun 30, 2023
Abstract
An elevated wide variety of teens and youngsters with ovarian tumors have been managed with ovarian-sparing surgical treatment in the final few years. However, complete statistics on fertility results and nearby relapse are scarce. In this study, we systematically describe the modern results of ovarian-sparing surgery, as said in the literature. Borderline ovarian tumors are a one-of-a-kind category of ovarian tumors between benign and malignant, which are now not touchy to common chemotherapy regimens, and the improvement of goal capsules is restricted due to the lack of telephone lines. Tumor organoids can nicely maintain the genetic traits of the fundamental tumor, however there are solely a few reviews of utility in borderline tumors. In this study, we correctly generated thirteen ovarian borderline tumor organoids and examined the antitumor recreation of Bractoppin, a BRCA1 carboxy-terminal area (BRCT) inhibitor.
Citation: Jain D (2023) Preserving Genetic Traits: Characterizing Ovarian Borderline Tumor Organoids and Evaluating the Antitumor Activity of Bractoppin, a BRCA1 Carboxy-Terminal Domain (BRCT) Inhibitor. Current Trends Gynecol Oncol, 8: 157. Doi: 10.4172/ctgo.1000157
Copyright: © 2023 Jain D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Tools
Article Usage
- Total views: 562
- [From(publication date): 0-2023 - Feb 28, 2025]
- Breakdown by view type
- HTML page views: 481
- PDF downloads: 81